Article Text

Download PDFPDF

AB0320 Rheumatoid arthritis in brazil – the “real” study: a nationwide prospective study
  1. G Castelar-Pinheiro1,
  2. AB Vargas-Santos1,
  3. C Albuquerque2,
  4. R Amorim1,
  5. R Giorgi3,
  6. S Radominski4,
  7. I Pereira5,
  8. MF Guimarães6,
  9. M Bértolo7,
  10. P Louzada Jr.8,
  11. MF Cunha9,
  12. K Bonfiglioli10,
  13. C Brenol11,
  14. LMH Mota2
  1. 1Internal Medicine, Rheumatology Unit, Universidade do Estado do Rio de Janeiro, Rio de Janeiro
  2. 2Universidade de Brasília, Brasília
  3. 3Instituto de Assistência Médica ao Servidor Público Estadual, São Paulo
  4. 4Universidade Federal do Paraná, Curitiba
  5. 5Universidade Federal de Santa Catarina, Florianόpolis
  6. 6Universidade Federal de Minas Gerais, Belo Horizonte
  7. 7Universidade Estadual de Campinas, Campinas
  8. 8Universidade de São Paulo - Ribeirão Preto, Ribeirão Preto
  9. 9Universidade Federal do Pará, Belém
  10. 10Universidade de São Paulo, São Paulo
  11. 11Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil


Background Early diagnosis and immediate treatment are critical in achieving optimal outcomes in rheumatoid arthritis (RA). However, anecdotal evidence suggests that in Brazil there is still a significant delay in patient referral, RA diagnosis and DMARD initiation. The lack of national data hinders effective advocacy for proper public health policies, which led the RA commission of the Brazilian Society of Rheumatology to create a nationally-representative multicenter RA cohort to provide the necessary data.

Objectives To describe the development process and baseline characteristics of a large, nationally-representative multicenter cohort of RA patients in Brazil.

Methods Eleven public rheumatology centers from all of the 5 regions of Brazil enrolled ∼100 consecutive RA patients each (1987 ARA or 2010 ACR-EULAR). This cohort is being followed prospectively for 1 year, with systematic data collection at time 0, 6±1 months and 12±1 months, and registration of all other visits during this 1-year period. Data collection began in 08–2015, using a single online electronic medical record, and included demographic, socioeconomic, clinical, lab, radiographic and therapeutic characteristics, along with functional status, quality of life and adherence to treatment information.

Results 1125 patients were enrolled (Table), ∼90% were female, with a mean age of 56 years and median disease duration of 13 years. Median BMI was 27 kg/m2, with 64% of the patients classified as overweight or obese. The interval between symptoms and diagnosis varied from 1 to 457 months (median 12 months). Almost half of the patients were on glucocorticoids, 96% on DMARDs, with 36% on biologics. Only 7% were seronegative for both rheumatoid factor and ACPA. Median HAQ-DI was 0.875 and median DAS28-ESR was 3.5, with 58.6% of patients presenting moderate or high disease activity.

Table 1.

Patients baseline characteristics

Conclusions The delay in diagnosis may explain the high percentage of patients with moderate or high disease activity and erosive disease. The low level of physical dysfunction observed in this established, predominantly seropositive RA population may be explained by the large proportion of patients on glucocorticoid and biologic therapy. Our findings suggest that, despite current treatment concepts being well known and accepted by Brazilian rheumatologists, there is still a gap in early diagnosis and management of RA.

Disclosure of Interest None declared

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.